Subscribe To
AMGN / Analysis: FTC settlement could shelter Amgen from US price cuts, taxes
AMGN News
By MarketBeat
November 1, 2023
5 Dow stocks to track during the market correction
The Dow Jones Industrial Average of blue chip stocks is trading higher for the week, but is still in correction territory, having posted losses in eac more_horizontal
By Market Watch
October 31, 2023
Amgen gets FDA approval for its inflammatory diseases treatment Wezlana
Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases. more_horizontal
By Reuters
October 31, 2023
U.S. FDA approves Amgen's biosimilar vesrion of J&J's Stelara
The U.S. Food and Drug Administration on Tuesday approved Amgen's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment Stelara fo more_horizontal
By Yahoo Finance
October 31, 2023
Amgen's obesity drug plans, outlook for 2024
Amgen (AMGN) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acqu more_horizontal
By Zacks Investment Research
October 31, 2023
Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View
Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guid more_horizontal
By Zacks Investment Research
October 31, 2023
Amgen (AMGN) Q3 Earnings Top Estimates
Amgen (AMGN) came out with quarterly earnings of $4.96 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings o more_horizontal
By Proactive Investors
October 31, 2023
Amgen stock unmoved by earnings beat
In contrast to market expectations, shares of Amgen, Inc. (NASDAQ:AMGN) remained flat even as the biotechnology giant exceeded third-quarter earnings more_horizontal
By Market Watch
October 31, 2023
Amgen's stock jumps premarket after earnings beat and company again raises guidance
Amgen Inc.'s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again r more_horizontal